GlassScriptPhysician profile
Phillip P Beck
NPI 1700236882
$7,188.61
in general payments reported to CMS, 2019-2025
45 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.00 · 2021: $175 · 2022: $1,423 · 2023: $1,666 · 2024: $2,289 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,566 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,566.35 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,196.29 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $900.40 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $752.79 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Gilead Sciences, INC. | $712.43 | 2021-2025 | Biktarvy, Epclusa |
| Aimmune Therapeutics, INC. | $506.19 | 2024-2025 | Vowst |
| Insmed, INC. | $425.04 | 2021-2025 | Arikayce |
| Dexcom, INC. | $355.05 | 2022-2024 | Dexcom G6 Transmitter |
| Shionogi INC | $281.60 | 2022-2024 | Fetroja |
| Recordati_rare_diseases_inc. | $206.35 | 2024-2025 | Isturisa, Signifor Lar, Sylvant |
| Lilly USA, LLC | $197.76 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $165.68 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Melinta Therapeutics, LLC | $127.09 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $117.70 | 2024-2025 | Nuzyra |
| Amgen INC. | $111.96 | 2022-2024 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $101.15 | 2024-2025 | Korlym |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $92.50 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $79.79 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $79.01 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $76.09 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.64 | 2021-2022 | |
| Radius Health, INC. | $62.20 | 2023-2025 | Tymlos |
| Ferring Pharmaceuticals INC. | $46.33 | 2023-2024 | Rebyota |
| Kyowa Kirin, INC. | $42.99 | 2023-2025 | Crysvita |
| Bio Products Laboratory USA, INC. | $36.57 | 2022 | |
| La Jolla Pharmaceutical Company | $35.32 | 2024-2025 | Xacduro |
| Averitas Pharma INC. | $34.67 | 2024 | Qutenza |
| Beta Bionics, INC. | $30.80 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Organogenesis INC. | $27.44 | 2022-2023 | Puraply |
| Ascendis Pharma Endocrinology INC | $26.61 | 2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $23.69 | 2022 | |
| Janssen Biotech, INC. | $23.19 | 2022 | |
| Medtronic, INC. | $21.17 | 2024 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $20.41 | 2025 | |
| Chiesi USA, INC. | $19.92 | 2024 | Mycapssa |
| Abbott Laboratories | $19.74 | 2022 | |
| Grifols USA, LLC | $18.29 | 2021 | |
| Astellas Pharma US INC | $17.75 | 2023 | Cresemba |
| Pfizer INC. | $17.10 | 2023 | |
| Harmony Biosciences LLC | $17.06 | 2021 | |
| Cequr Corporation | $17.04 | 2024 | Cequr Simplicity |
| Nevro Corp. | $15.46 | 2022 | |
| Neurocrine Biosciences, INC. | $15.07 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $14.18 | 2023 | Imcivree |
| Glaxosmithkline, LLC. | $13.70 | 2025 | Penmenvy, Shingrix, Arexvy |
| Amneal Pharmaceuticals LLC | $13.40 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.